LeMaitre Vascular, Inc.

LeMaitre Vascular, Inc. is an American medical device company headquartered in Burlington, Massachusetts, specializing in the development, manufacturing, and marketing of medical devices and implants. The company also provides human tissue cryopreservation services, primarily focusing on the treatment of vascular conditions such as peripheral vascular disease, end-stage renal disease, and cardiovascular disease. Its mission is to provide surgeons and interventionalists worldwide with innovative devices and information to diagnose and heal the sick, aiming to restore blood flow in the peripheral vasculature and improve patient outcomes.

The company's diversified product portfolio includes a wide range of disposable and implantable vascular devices. Key offerings encompass valvulotomes, embolectomy catheters, carotid shunts, various grafts (e.g., ePTFE, polyester, collagen vascular grafts like Artegraft), and biologic patches such as the XenoSure bovine pericardium patch. Additionally, LeMaitre Vascular provides human tissue cryopreservation services, including cryopreserved human tissue grafts (RestoreFlow allografts). The company primarily targets vascular surgeons, along with cardiac, general, and neurosurgeons, and operates globally, selling directly to hospitals in over 25 countries and through distributors in more than 70 countries.

Led by Chairman and CEO George W. LeMaitre, the company reported strong financial results for 2025, with record revenues exceeding $228 million and gross margins near 68%. In February 2026, LeMaitre Vascular announced a new US$100 million share repurchase program and a 25% dividend increase, reflecting confidence in its business. The company holds a dominant market position in open vascular surgery, with an estimated 60% share of the valvulotome market and a leading role in bovine patch sales as of early 2026. LeMaitre Vascular maintains a strong balance sheet, with no debt and over $100 million in cash as of early 2026, which supports its strategy of pursuing niche markets and strategic acquisitions.